Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Dehydrocurvularin is a potent antineoplastic agent irreversibly blocking ATP-citrate lyase: evidence from chemoproteomics.

Deng Z, Wong NK, Guo Z, Zou K, Xiao Y, Zhou Y.

Chem Commun (Camb). 2019 Apr 4;55(29):4194-4197. doi: 10.1039/c9cc00256a.

PMID:
30895984
2.

ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.

Granchi C.

Eur J Med Chem. 2018 Sep 5;157:1276-1291. doi: 10.1016/j.ejmech.2018.09.001. Epub 2018 Sep 1. Review.

PMID:
30195238
3.

ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment.

Khwairakpam AD, Shyamananda MS, Sailo BL, Rathnakaram SR, Padmavathi G, Kotoky J, Kunnumakkara AB.

Curr Drug Targets. 2015;16(2):156-63. Review.

PMID:
25537655
4.

Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact.

Migita T, Okabe S, Ikeda K, Igarashi S, Sugawara S, Tomida A, Taguchi R, Soga T, Seimiya H.

Am J Pathol. 2013 May;182(5):1800-10. doi: 10.1016/j.ajpath.2013.01.048. Epub 2013 Mar 15.

PMID:
23506848
5.

Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.

Koerner SK, Hanai JI, Bai S, Jernigan FE, Oki M, Komaba C, Shuto E, Sukhatme VP, Sun L.

Eur J Med Chem. 2017 Jan 27;126:920-928. doi: 10.1016/j.ejmech.2016.12.018. Epub 2016 Dec 9.

PMID:
27997879
6.

ATP citrate lyase inhibitors as novel cancer therapeutic agents.

Zu XY, Zhang QH, Liu JH, Cao RX, Zhong J, Yi GH, Quan ZH, Pizzorno G.

Recent Pat Anticancer Drug Discov. 2012 May 1;7(2):154-67. Review.

PMID:
22339355
7.

The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076.

Pearce NJ, Yates JW, Berkhout TA, Jackson B, Tew D, Boyd H, Camilleri P, Sweeney P, Gribble AD, Shaw A, Groot PH.

Biochem J. 1998 Aug 15;334 ( Pt 1):113-9.

8.

Targeting mitochondrial citrate transport in breast cancer cell lines.

Ozkaya AB, Ak H, Atay S, Aydin HH.

Anticancer Agents Med Chem. 2015;15(3):374-81.

PMID:
25511512
9.

ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.

Burke AC, Huff MW.

Curr Opin Lipidol. 2017 Apr;28(2):193-200. doi: 10.1097/MOL.0000000000000390. Review.

PMID:
28059952
10.

miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.

Xin M, Qiao Z, Li J, Liu J, Song S, Zhao X, Miao P, Tang T, Wang L, Liu W, Yang X, Dai K, Huang G.

Oncotarget. 2016 Jul 12;7(28):44252-44265. doi: 10.18632/oncotarget.10020.

11.

Radicicol binds and inhibits mammalian ATP citrate lyase.

Ki SW, Ishigami K, Kitahara T, Kasahara K, Yoshida M, Horinouchi S.

J Biol Chem. 2000 Dec 15;275(50):39231-6.

12.

Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism.

Shah S, Carriveau WJ, Li J, Campbell SL, Kopinski PK, Lim HW, Daurio N, Trefely S, Won KJ, Wallace DC, Koumenis C, Mancuso A, Wellen KE.

Oncotarget. 2016 Jul 12;7(28):43713-43730. doi: 10.18632/oncotarget.9666.

13.

ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme.

Gribble AD, Dolle RE, Shaw A, McNair D, Novelli R, Novelli CE, Slingsby BP, Shah VP, Tew D, Saxty BA, Allen M, Groot PH, Pearce N, Yates J.

J Med Chem. 1996 Aug 30;39(18):3569-84.

PMID:
8784456
14.

Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells.

Migita T, Okabe S, Ikeda K, Igarashi S, Sugawara S, Tomida A, Soga T, Taguchi R, Seimiya H.

Int J Cancer. 2014 Jul 1;135(1):37-47. doi: 10.1002/ijc.28652. Epub 2013 Dec 18.

15.

Inhibition of ATP citrate lyase (ACLY) protects airway epithelia from PM2.5-induced epithelial-mesenchymal transition.

Fu Y, Lu R, Cui J, Sun H, Yang H, Meng Q, Wu S, Aschner M, Li X, Chen R.

Ecotoxicol Environ Saf. 2019 Jan 15;167:309-316. doi: 10.1016/j.ecoenv.2018.10.033. Epub 2018 Oct 18.

PMID:
30343145
16.

Energy deregulation: licensing tumors to grow.

Garber K.

Science. 2006 May 26;312(5777):1158-9. No abstract available.

PMID:
16728625
17.

Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth.

Gao Y, Islam MS, Tian J, Lui VW, Xiao D.

Cancer Lett. 2014 Jul 10;349(1):15-25. doi: 10.1016/j.canlet.2014.03.015. Epub 2014 Mar 29.

PMID:
24690568
18.

Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas.

Beckner ME, Fellows-Mayle W, Zhang Z, Agostino NR, Kant JA, Day BW, Pollack IF.

Int J Cancer. 2010 May 15;126(10):2282-95. doi: 10.1002/ijc.24918.

19.

ATP-citrate lyase reduction mediates palmitate-induced apoptosis in pancreatic beta cells.

Chu KY, Lin Y, Hendel A, Kulpa JE, Brownsey RW, Johnson JD.

J Biol Chem. 2010 Oct 15;285(42):32606-15. doi: 10.1074/jbc.M110.157172. Epub 2010 Aug 7.

20.

Mendelian Randomization Study of ACLY and Cardiovascular Disease.

Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Kastelein JJP, Nicholls SJ.

N Engl J Med. 2019 Mar 14;380(11):1033-1042. doi: 10.1056/NEJMoa1806747.

Supplemental Content

Support Center